Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004870 · ClinicalTrials.gov registry record · Phase 1
Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer
A Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00004870: Completed Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
NCT00004870 is a Phase 1 study that has completed, run by The University of Texas Health Science Center at San Antonio. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004870, a Phase 1 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Gene therapy such as oblimersen may make tumor cells more sensitive to chemotherapy drugs. Combining irinotecan and oblimersen may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining oblimersen and irinotecan in treating patients who have metastatic or recurrent colorectal cancer.
Interventions
- DRUG irinotecan hydrochloride
- BIOLOGICAL oblimersen sodium
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-06 |
| Est. Completion | 2002-09 |
| Phase | Phase 1 |
What the finished NCT00004870 record still lists
NCT00004870 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which irinotecan hydrochloride is the first listed.
NCT00004870 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004870 about?
NCT00004870 is a clinical study titled "Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Gene therapy such as oblimersen may make tumor cells more sensitive to chemotherapy drugs. Combining irinotecan and oblimersen may kill more tumor cells. PURPOSE: Phase I/II trial...
What is the current status of trial NCT00004870?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-06. Estimated completion is 2002-09.
What interventions are being tested in trial NCT00004870?
The interventions under investigation include: irinotecan hydrochloride (DRUG), oblimersen sodium (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004870?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia